<DOC>
	<DOCNO>NCT01948518</DOCNO>
	<brief_summary>The purpose study investigate acute effect sildenafil diffusion capacity , commonly perform pulmonary function test , use assess lung ' gas exchange capability . This study ass safety efficacy drug . The study clinical end point . The variable study diffusion capacity 6 minute walk single dose sildenafil . This study complete .</brief_summary>
	<brief_title>Effect Sildenafil Diffusion Capacity Patients With PH Parenchymal Lung Disease</brief_title>
	<detailed_description>Sildenafil cyclic GMP selective phosphodiesterase type 5 inhibitor approve use FDA patient pulmonary arterial hypertension . There recent interest use drug patient diffuse parenchymal lung disease . This largely base sildenafil 's salutary effect observe small study ( Collard et al . 897-99 ; Ghofrani et al . 895-900 ; Collard et al . 897-99 ) frequent coexistence pulmonary hypertension patient ( Nathan et al . 657-63 ) . In eight patient pulmonary fibrosis pulmonary hypertension , sildenafil reduce pulmonary artery pressure improve shunt fraction determine multiple inert gas elimination technique ( Ghofrani et al . 895-900 ; Nathan et al . 657-63 ) . Collard et al demonstrate 49 meter improvement 6 minute walk distance 11 patient idiopathic pulmonary fibrosis pulmonary hypertension 3 month therapy sildenafil . Main theoretical concern use pulmonary arterial vasodilator therapy worsen ventilation perfusion match due release hypoxic vasoconstriction . Such phenomenon well recognize prostacyclin infusion ( Ghofrani et al . 895-900 ; Walmrath et al . 1084-92 ) . Inhaled route seem circumvent side effect preferentially deliver drug alveoli high V/Q ratio augment blood flow region ( Ghofrani et al . 895-900 ; Walmrath et al . 1084-92 ) . In study address possible effect systemically administer sildenafil gas exchange , Ghofrani et al observed improvement V/Q match eight patient use multiple inert gas elimination technique ( MIGET ) . The author postulate enhancement local defense mechanism hypoxia i.e . increase nitric oxide availability hypoxic alveolus despite oral route administration ( Ghofrani et al . 895-900 ) . In recent study 14 normal subject , oral sildenafil effect DLCO measurement rest , exercise hypoxic condition ( Snyder et al . 421-30 ) . Diffusion capacity lung carbon monoxide ( DLCO ) clinically available method assess gas exchange practitioner . It frequently use tool serial monitoring diffuse parenchymal lung disease . American Thoracic Society endorse use assessment patient idiopathic interstitial pneumonia ( American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification Idiopathic Interstitial Pneumonias . This Joint Statement American Thoracic Society ( ATS ) , European Respiratory Society ( ERS ) adopt ATS Board Directors , June 2001 The ERS Executive Committee , June 2001 277-304 ) . The aim study delineate effect orally administer sildenafil diffusion capacity ( absolute value ) . The significance information twofold . First , would helpful clinically determine contribution pulmonary vasodilator change DLCO separate effect true clinical change . Second , sildenafil 's effect gas exchange may lead modification therapy change oxygen flow deliver patient . This study measure clinical outcome safety sildenafil . A single dose administer effect diffusion capacity 6 minute walk assess compare baseline . While would caution clinician rare exception finding , believe data exclude significant confound effect interpretation diffusion capacity patient parenchymal lung disease treat pulmonary hypertension oral sildenafil . Whether conclusion hold true high dos sildenafil patient vasodilator response may offer venue research . We ask retrospectively register study request BMC Pulmonary Medicine Journal Editorial Office prior publication .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Adult patient age 18 year age able consent Diagnosis diffuse parenchymal lung disease concomitant pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Parenchymal Lung Disease</keyword>
	<keyword>Diffusion Capacity</keyword>
</DOC>